Press Releases

afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections CARB-X Clinical Trials CPP cyclosporin A Debio 0123 Debio 025 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1460 Debio 1561 Debio 1562 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Life Sciences Award Debiovision EPFL EPI-hNE4 FibroTrap fuze H3 Pharma Huperzine-A JCA-Mauvernay Award Moapar Muscular Dystrophy naratuximab emtansine (Debio 1562) Oncology Chair Oxaliplatin PLGA Spinomix Tremelimumab Triptorelin

June 12, 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

June 3, 2019

Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…

May 21, 2019

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

May 14, 2019

Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug

April 1, 2019

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

February 26, 2019

Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

February 14, 2019

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…

January 7, 2019

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

October 11, 2018

Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…

First
Previous
1
2
…
22
Next
Last